Disease Burden, Treatment Patterns and Asthma Control in Adult Patients with Asthma in China: A Real-World Study
Victoria Benson,James Siddall,Adam Haq,Mark Small,Rafael Alfonso-Cristancho,Zhiliu Tang,Peter Howarth,Tao Ye,Anna Richards
DOI: https://doi.org/10.2147/jaa.s460300
2024-10-01
Journal of Asthma and Allergy
Abstract:Victoria S Benson, 1, &ast James Siddall, 2, &ast Adam Haq, 2 Mark Small, 2 Rafael Alfonso-Cristancho, 3 Zhiliu Tang, 4 Peter Howarth, 5 Tao Ye, 6 Anna Richards 7 1 Epidemiology, Value Evidence & Outcomes, GSK, London, UK; 2 Adelphi Real World, Bollington, UK; 3 Value Evidence & Outcomes, GSK, Philadelphia, Pennsylvania, USA; 4 Value Evidence & Outcomes, GSK, Shanghai, People's Republic of China; 5 Global Respiratory Franchise, GSK, Brentford, UK; 6 Medical Affairs, Respiratory, GSK, Shanghai, People's Republic of China; 7 Value Evidence & Outcomes, GSK, Brentford, UK &astThese authors contributed equally to this work Correspondence: Tao Ye, Medical Affairs, Respiratory, GSK, 902 halei Road, Pudong, Shanghai, People's Republic of China, Email Purpose: To inform better asthma management in China, this study aimed to comprehensively investigate clinical characteristics, treatment patterns, asthma control status, exacerbations, and humanistic burden among adult patients seeking hospital-based asthma care by analyzing data from Adelphi Asthma Disease Specific Program conducted in China. Patients and Methods: All information was collected on survey date (August–December 2018) from medical records, physicians, or patients, without follow-up being conducted. Results are summarized descriptively for the overall population as well as subgroups defined by GINA 2018 treatment step. Results: Of the included 765 patients, 46.0%, 40.4%, and 29.2% had undergone lung function, blood eosinophil count, and specific immunoglobulin E/radioallergosorbent testing, and 17.2%, 24.1%, and 58.7% were managed at GINA Steps 1– 2, 3, and 4– 5, respectively. Asthma was not well controlled in 57.3% of patients based on definitions adapted from the ERS/ATS and 10.7% of patients had experienced ≥ 1 severe exacerbation in the preceding year. According to patient self-reporting (n=603), the mean (SD) was 0.9 (0.1) for utility on EQ-5D-3L and was 7.8% (10.4%), 36.9% (20.0%), 40.8% (22.2%), and 37.9% (22.3%) for absenteeism, presenteeism, work productivity loss, and activity impairment, respectively, on WPAI. Both asthma control and humanistic burden worsened with progressive GINA treatment steps. Conclusion: In patients seeking hospital-based asthma care in China, lung function and biomarker tests were underutilized, impairment in productivity and quality of life was observed, and more than half did not achieve well-controlled asthma despite approximately 60% being managed at GINA treatment Steps 4– 5. These findings highlight the urgent need for optimizing asthma management in China. Keywords: asthma control, exacerbation, treatment patterns, health care resource utilization, humanistic burden Asthma is a chronic respiratory disease characterized by chronic airway inflammation and airway remodeling, which causes reversible narrowing of the airways and consequently difficulty in breathing. 1 In 2019, asthma was estimated to affect 262 million people worldwide, equivalent to a prevalence of 3.4%. 2 The prevalence of asthma in China was estimated to be 4.2%, representing 45.7 million patients, according to the national, cross-sectional China Pulmonary Health (CPH) study performed between 2012 and 2015. 3 Asthma is largely underdiagnosed in China. The CPH study found that only 28.8% of asthma patients had ever been physician-diagnosed and 23.4% had ever received a lung function test, most likely due to the low awareness of asthma in both patients and physicians, the limited availability of equipment in primary care, and a lack of well-trained healthcare professionals (HCPs), especially in rural areas. 3,4 Sustained asthma control, an essential goal of asthma management, 5,6 can reduce healthcare resource utilization (HCRU) and improve quality of life. 7–9 However, the proportion of Chinese patients with well-controlled asthma has consistently been shown to be unsatisfactory across studies, ranging from 14% to 61% across different definitions of asthma control and disease severity. 10–12 Given the sub-optimal control, China is faced with a heavy burden from asthma, despite the declining asthma-related mortality recorded in recent years. 13 In the CPH study, 15.5% and 7.2% of asthma patients reported emergency room (ER) visits and hospitalizations, respectively, due to exacerbations within the preceding year. 3 Even in patients with mild asthma, 14.0% visited ER and 3.1% were hospitalized due to exacerbations in the preceding year, according to the Respiratory -Abstract Truncated-
immunology,allergy,respiratory system